Atlas Trials

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Clinical trial NCT06649344 · COMPLETED

Trial details

NCT number
NCT06649344
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Type 2 Diabetes
Start date
2024-10-31
Primary completion
2026-07-18
Enrollment
884

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.